Literature DB >> 2443128

The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin.

F A Ofosu, P Sie, G J Modi, F Fernandez, M R Buchanan, M A Blajchman, B Boneu, J Hirsh.   

Abstract

Heparin catalyses the inhibition of two key enzymes of blood coagulation, namely Factor Xa and thrombin, by enhancing the antiproteinase activities of plasma antithrombin III and heparin cofactor II. In addition, heparin can directly inhibit the activation of Factor X and prothrombin. The contributions of each of these effects to the anticoagulant activity of heparin have not been delineated. We therefore performed experiments to assess how each of these effects of heparin contributes to its anticoagulant activity by comparing the effects of heparin, pentosan polysulphate and D-Phe-Pro-Arg-CH2Cl on the intrinsic pathway of coagulation. Unlike heparin, pentosan polysulphate catalyses only the inhibition of thrombin by plasma. D-Phe-Pro-Arg-CH2Cl is rapid enough an inhibitor of thrombin so that when added to plasma no complexes of thrombin with its inhibitors are formed, whether or not the plasma also contains heparin. Heparin (0.66 microgram/ml) and pentosan polysulphate (6.6 micrograms/ml) completely inhibited the intrinsic-pathway activation of 125I-prothrombin to 125I-prothrombin fragment 1 + 2 and 125I-thrombin. On the addition of thrombin, a good Factor V activator, to the plasma before each sulphated polysaccharide, the inhibition of prothrombin activation was demonstrable only in the presence of higher concentrations of the sulphated polysaccharide. D-Phe-Pro-Arg-CH2Cl also completely inhibited the intrinsic-pathway activation of prothrombin in normal plasma. The inhibitory effect of D-Phe-Pro-Arg-CH2Cl was reversed if thrombin was added to the plasma before D-Phe-Pro-Arg-CH2Cl. The inhibition of the activation of prothrombin by the three agents was also abolished with longer times with re-added Ca2+. Reversal of the inhibitory effects of heparin and pentosan polysulphate was associated with the accelerated formation of 125I-thrombin-antithrombin III and 125I-thrombin-heparin cofactor complexes respectively. These results suggest that the anticoagulant effects of heparin and pentosan polysulphate are mediated primarily by their ability to inhibit the thrombin-dependent activation of Factor V, thereby inhibiting the formation of prothrombinase complex, the physiological activator of prothrombin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443128      PMCID: PMC1147894          DOI: 10.1042/bj2430579

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  31 in total

1.  Prevention of postoperative thromboembolic complications. A prospective comparison between dextran 70, dihydroergotamine heparin and a sulphated polysaccharide.

Authors:  D Bergqvist; H O Efsing; T Hallböök; B Lindblad
Journal:  Acta Chir Scand       Date:  1980

Review 2.  Chemistry of the hemostatic mechanism and its relationship to the action of heparin.

Authors:  R D Rosenberg
Journal:  Fed Proc       Date:  1977-01

Review 3.  Natural anticoagulant mechanisms.

Authors:  R D Rosenberg; J S Rosenberg
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

4.  The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III.

Authors:  F Ofosu; M A Blajchman; J Hirsh
Journal:  Thromb Res       Date:  1980-11-15       Impact factor: 3.944

5.  The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin.

Authors:  R E Jordan; G M Oosta; W T Gardner; R D Rosenberg
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

6.  D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin.

Authors:  C Kettner; E Shaw
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

7.  Interactions between heparin and factor Xa. Inhibition of prothrombin activation.

Authors:  F J Walker; C T Esmon
Journal:  Biochim Biophys Acta       Date:  1979-07-04

8.  Coordinate binding of factor Va and factor Xa to the unstimulated platelet.

Authors:  P B Tracy; M E Nesheim; K G Mann
Journal:  J Biol Chem       Date:  1981-01-25       Impact factor: 5.157

9.  The role of phospholipids and factor Va in the prothrombinase complex.

Authors:  J Rosing; G Tans; J W Govers-Riemslag; R F Zwaal; H C Hemker
Journal:  J Biol Chem       Date:  1980-01-10       Impact factor: 5.157

10.  Preparation and properties of bovine factor VIII (antihemophilic factor).

Authors:  G A Vehar; E W Davie
Journal:  Biochemistry       Date:  1980-02-05       Impact factor: 3.162

View more
  14 in total

1.  Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.

Authors:  X J Yang; M A Blajchman; S Craven; L M Smith; N Anvari; F A Ofosu
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

2.  Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.

Authors:  B Bray; D A Lane; J M Freyssinet; G Pejler; U Lindahl
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

3.  Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.

Authors:  F A Ofosu; J W Fenton; J Maraganore; M A Blajchman; X Yang; L Smith; N Anvari; M R Buchanan; J Hirsh
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

Review 4.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.

Authors:  M Andrew; L Mitchell; L Berry; B Paes; M Delorme; F Ofosu; R Burrows; B Khambalia
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

6.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

7.  Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.

Authors:  F A Ofosu; G J Modi; M A Blajchman; M R Buchanan; E A Johnson
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

8.  Antithrombin III activity (residual thrombin activity) in plasma from non-medicated or heparinized horses.

Authors:  B J Darien; J Potempa; J N Moore; J Travis
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

9.  Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.

Authors:  J F Eidt; P Allison; S Noble; J Ashton; P Golino; J McNatt; L M Buja; J T Willerson
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

10.  Hirudin as a molecular probe for thrombin in vitro and during systemic coagulation in the pig.

Authors:  P Zoldhelyi; J H Chesebro; W G Owen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.